Docoh
Loading...

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PRPO Precipio Inc
29 Apr 21
Definitive proxy
4:31pm
Officer of Resolys Bio, Inc, a privately held pharmaceutical company focused on treating chronic traumatic brain injury, a position has held since September
8-K
EX-99.1
PRPO Precipio Inc
3 Mar 21
Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors
4:30pm
. Sandberg also serves as Chief Executive Officer of Resolys Bio, Inc, a pharmaceutical company which is developing a treatment for long-term, chronic
DEF 14A
PRPO Precipio Inc
29 Apr 20
Definitive proxy
4:32pm
, a privately held pharmaceutical company focused on treating chronic traumatic brain injury, a position has held since September 2017. He has also served
8-K
EX-99.1
PRPO Precipio Inc
4 Dec 19
Precipio Announces the Resignation of Samuel Riccitelli and the Introduction of Richard Sandberg to its Board of Directors
4:01pm
as Chief Executive Officer of Resolys Bio, Inc, a pharmaceutical company which is developing a pharmaceutical treatment for long-term, chronic traumatic
FWP
PRPO Precipio Inc
1 Aug 17
Free writing prospectus
8:00pm
this revolution + – – – – – – + + + + + + + + + ICP FUTURE POTENTIAL APPLICATIONS Companion Diagnostics Patients with CML (Chronic Myeloid Leukemia
FWP
PRPO Precipio Inc
31 Jul 17
Free writing prospectus
8:00pm
APPLICATIONS Companion Diagnostics Patients with CML (Chronic Myeloid Leukemia): Targeted therapy: Gleevec Companion diagnostic: BCR-ABL test Tested
10-Q
2013 Q3
PRPO Precipio Inc
13 Nov 13
Quarterly report
7:00pm
Americans suffer from chronic pain. Opioids, which include oxycodone and methadone, are widely used in the management of moderate to severe pain. While
8-K
PRPO Precipio Inc
19 Jun 05
Other Events
8:00pm
that are associated with development of resistance to imatinib therapy in Chronic Myeloid Leukemia (CML) patients. A copy of the press release is filed … in the BCR-ABL gene that are associated with development of resistance to imatinib therapy in Chronic Myeloid Leukemia (CML) patients
8-K
EX-99
PRPO Precipio Inc
19 Jun 05
Other Events
8:00pm
RESISTANCE MUTATIONS IN CHRONIC MYELOID LEUKEMIA STUDY IN JOURNAL OF CLINICAL ONCOLOGY HIGHLIGHTS RESULTS … of its WAVE System to enable detection of mutations in the BCR-ABL gene that are associated with development of resistance to imatinib therapy in Chronic
8-K
EX-99.1
PRPO Precipio Inc
3 Dec 03
Other events
7:00pm
inhibitor imatinib in chronic myeloid leukemia patients. The other study involves detection of small duplications and point mutations in the FLT3 gene
  • 1